Jean Edouard Frederic P. Rivier

Jean Edouard Frederic P. Rivier's AcademicInfluence.com Rankings

Biology

#2464

World Rank

#3901

Historical Rank

Biochemistry

#205

World Rank

#259

Historical Rank

biology Degrees

Download Badge

Biology

Jean Edouard Frederic P. Rivier's Degrees

PhD Biochemistry University of Geneva

Why Is Jean Edouard Frederic P. Rivier Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jean Edouard Frederic P. Rivier's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin (1981) (3784)
Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing (1983) (2215)
Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor (1995) (1494)
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. (1982) (1234)
Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid (1986) (1181)
Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour (1982) (1061)
Functional Amyloids As Natural Storage of Peptide Hormones in Pituitary Secretory Granules (2009) (878)
Corticotropin releasing factor produces behavioural activation in rats (1982) (747)
Peptide neurotoxins from fish-hunting cone snails. (1985) (702)
Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. (1982) (667)
Effects of synthetic ovine corticotropin-releasing factor, glucocorticoids, catecholamines, neurohypophysial peptides, and other substances on cultured corticotropic cells. (1983) (571)
Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. (1982) (556)
In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. (1982) (552)
Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. (1986) (544)
Diversity of Conus neuropeptides. (1990) (529)
Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A (1993) (467)
Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. (1984) (465)
Heterodimers and homodimers of inhibin subunits have different paracrine action in the modulation of luteinizing hormone-stimulated androgen biosynthesis. (1987) (448)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors (2006) (431)
Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. (1984) (408)
Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF) (LH-hypothalamus-LRF-gas chromatography-mass spectrometry-decapeptide-Edman degradation). (1972) (406)
Primary structure of corticotropin-releasing factor from ovine hypothalamus. (1981) (405)
Chemical and biological characterization of corticotropin releasing factor. (1983) (379)
Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptide (1983) (379)
Corticotropin releasing factor (CRF): immunoreactive neurones and fibers in rat hypothalamus (1982) (364)
Characterization of rat hypothalamic growth hormone-releasing factor (1983) (361)
Early weaning stress impairs development of mucosal barrier function in the porcine intestine. (2010) (356)
Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta (1987) (328)
Characterization of a teleost gonadotropin-releasing hormone. (1983) (323)
Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats (1983) (320)
Peptides: Chemistry, Structure and Biology (1990) (319)
Corticotropin releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. (1983) (316)
Use of Trialkyl Ammonium Phosphate (TAAP) Buffers in Reverse Phase HPLC for High Resolution and High Recovery of Peptides and Proteins (1978) (301)
Characterization of rat hypothalamic corticotropin-releasing factor. (1983) (299)
Key role of CRF in the skin stress response system. (2013) (294)
Purification and partial characterization of inhibin from porcine follicular fluid. (1985) (292)
Bombesin:potent effects on thermoregulation in the rat. (1977) (288)
Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat (1983) (286)
Importance of FSH-releasing protein and inhibin in erythrodifferentiation (1987) (275)
Inhibition of adrenocorticotropic hormone secretion in the rat by immunoneutralization of corticotropin-releasing factor. (1982) (272)
Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. (1981) (263)
Corticotropin-releasing factor (CRF): central effects on mean arterial pressure and heart rate in rats. (1982) (262)
Localization, secretion, and action of inhibin in human placenta. (1987) (262)
CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat (2005) (261)
Production and regulation of inhibin subunits in pituitary gonadotropes. (1989) (259)
Corticotropin-releasing factor: effects on the sympathetic nervous system and oxygen consumption. (1982) (259)
Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. (1984) (256)
Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor. (1988) (247)
Effects of synthetic human pancreatic (tumor) GH releasing factor and somatostatin, triiodothyronine and dexamethasone on GH secretion in vitro. (1983) (244)
Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. (2009) (243)
Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol. (1983) (242)
Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells (1984) (241)
"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. (1982) (234)
Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. (1974) (232)
Goldfish ghrelin: molecular characterization of the complementary deoxyribonucleic acid, partial gene structure and evidence for its stimulatory role in food intake. (2002) (223)
Corticotropin releasing factor (CRF) receptor antagonist blocks activating and ‘anxiogenic’ actions of CRF in the rat (1986) (222)
[38] Assay of corticotropin releasing factor (1983) (215)
Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. (1995) (215)
Inhibin A-subunit cDNAs from porcine ovary and human placenta. (1986) (209)
Inhibin-mediated feedback control of follicle-stimulating hormone secretion in the female rat. (1986) (207)
Interaction of bombesin and litorin with specific membrane receptors on pancreatic acinar cells. (1978) (207)
Hormonal regulation of granulosa cell inhibin biosynthesis. (1986) (203)
Amyloid as a Depot for the Formulation of Long-Acting Drugs (2008) (202)
Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. (1984) (196)
Corticotropin-releasing factor antagonist attenuates the “anxiogenic-like” effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats (1999) (195)
NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. (2004) (192)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study (2014) (191)
The antinociceptive effects of spinally administered neuropeptide Y in the rat: systematic studies on structure-activity relationship. (1991) (190)
Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. (1994) (189)
A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. (1983) (189)
Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. (1985) (187)
The use of mass spectrometry in deducing the sequence of somatostatin--a hypothalamic polypeptide that inhibits the secretion of growth hormone. (1973) (187)
Bombesin-like activity: radioimmunologic assessment in biological tissues. (1978) (186)
Cardiac inotropic actions of urocortin in conscious sheep. (1997) (182)
Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice (2004) (180)
Characterization of a bipartite activator domain in transcription factor CREB (1990) (179)
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. (2006) (178)
CRF Induces Intestinal Epithelial Barrier Injury via the Release of Mast Cell Proteases and TNF-α (2012) (175)
Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. (1996) (175)
High affinity binding sites for a somatostatin-28 analog in rat brain. (1981) (174)
Corticotropin-releasing factor and the brain-gut motor response to stress. (1999) (171)
Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. (1997) (171)
Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. (1984) (171)
A nicotinic acetylcholine receptor ligand of unique specificity, alpha-conotoxin ImI. (1994) (168)
Biologic and immunologic activities and applications of somatostatin analogs. (1978) (166)
Inhibin β in central neural pathways involved in the control of oxytocin secretion (1988) (166)
Bombesin: Receptor distribution in brain and effects on nociception and locomotor activity (1980) (165)
Bombesin, bombesin analogues, and related peptides: effects on thermoregulation. (1978) (164)
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible (2011) (163)
Six novel gonadotropin-releasing hormones are encoded as triplets on each of two genes in the protochordate, Ciona intestinalis. (2003) (163)
Template-Assembled Synthetic Proteins with 4-Helix-Bundle Topology - Total Chemical Synthesis and Conformational Studies (1992) (163)
Corticotropin-releasing factor: a physiologic regulator of adrenal epinephrine secretion (1985) (161)
Chronic effects of [D-Trp6-Pro9-NEt]luteinizing hormone-releasing factor on reproductive processes in the female rat. (1978) (161)
Detection and purification of inhibin using antisera generated against synthetic peptide fragments. (1989) (159)
Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. (2002) (159)
Transmembrane topography of nicotinic acetylcholine receptor: immunochemical tests contradict theoretical predictions based on hydrophobicity profiles. (1986) (159)
Anatomic and phylogenetic distribution of somatostatin. (1976) (157)
Vasopressor receptor antagonist prevents behavioural effects of vasopressin (1981) (157)
Decrease in luteinizing hormone pulse frequency during a five-hour peripheral ghrelin infusion in the ovariectomized rhesus monkey. (2004) (155)
Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat. (1984) (155)
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. (2002) (154)
Effects of corticotropin releasing factor on locomotor activity in hypophysectomized rats (1985) (153)
Acceleration of growth in two children treated with human growth hormone-releasing factor. (1985) (151)
Inhibition of growth hormone secretion in the rat by synthetic somatostatin. (1974) (151)
Corticotropin-releasing factor antagonist blocks stress-induced fighting in rats (1987) (150)
Pituitary microadenomas causing Cushing's disease respond to corticotropin-releasing factor. (1982) (147)
Brain regulation of gastric secretion: influence of neuropeptides. (1980) (147)
Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide (2002) (145)
Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor (1983) (145)
Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation. (1983) (137)
Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist (2003) (136)
Corticotropin-Releasing Factor and Urocortin I Modulate Excitatory Glutamatergic Synaptic Transmission (2004) (135)
Reversed-phase high-performance liquid chromatography: preparative purification of synthetic peptides. (1984) (135)
Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. (2002) (132)
Location of antigenic determinants on primary sequences of subunits of nicotinic acetylcholine receptor by peptide mapping. (1986) (132)
Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. (2003) (132)
Stimulation of food intake in rats by centrally administered hypothalamic growth hormone-releasing factor (1985) (129)
New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. (1986) (128)
Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand (2007) (127)
Conantokin-T. A gamma-carboxyglutamate containing peptide with N-methyl-d-aspartate antagonist activity. (1990) (125)
Ligand requirements of the human corticotropin-releasing factor-binding protein. (1995) (125)
The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. (2004) (124)
The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men. (1980) (124)
Structure/Function Characterization of μ-Conotoxin KIIIA, an Analgesic, Nearly Irreversible Blocker of Mammalian Neuronal Sodium Channels* (2007) (124)
D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule. (1975) (123)
Neuronal pathways involved in abdominal surgery-induced gastric ileus in rats. (1996) (122)
Selective Activation of Corticotropin-Releasing Factor-2 Receptors on Neurochemically Identified Neurons in the Rat Dorsal Raphe Nucleus Reveals Dual Actions (2004) (122)
CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats (2005) (122)
A New Family of Conus Peptides Targeted to the Nicotinic Acetylcholine Receptor (*) (1995) (121)
Growth hormone-releasing factor binding sites in rat anterior pituitary membrane homogenates: modulation by glucocorticoids. (1985) (119)
The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. (1986) (119)
Corticotropin releasing factor receptor-mediated stimulation of adenylate cyclase activity in the rat brain (1986) (117)
Elevation of plasma neuropeptide Y levels in congestive heart failure. (1989) (117)
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications (2012) (117)
Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP. (1986) (116)
Central administration of a CRF antagonist blocks the development of stress-induced behavioral sensitization (1990) (115)
Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis. (1985) (115)
Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. (2009) (115)
Inactivation of a serotonin-gated ion channel by a polypeptide toxin from marine snails. (1998) (113)
Augmentation of ACTH-releasing activity of synthetic corticotropin releasing factor (CRF) by vasopressin in women. (1983) (112)
Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats. (2002) (111)
Neuronal calcium channel inhibitors. Synthesis of omega-conotoxin GVIA and effects on 45Ca uptake by synaptosomes. (1987) (111)
Bromocontryphan: post-translational bromination of tryptophan. (1997) (111)
Binding sites for growth hormone releasing factor on rat anterior pituitary cells (1985) (111)
Bomebesin: specific binding to rat brain membranes. (1978) (107)
Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. (1982) (106)
Corticotropin-Releasing Factor (CRF) Sensitization of Ethanol Withdrawal-Induced Anxiety-Like Behavior is Brain Site Specific and Mediated by CRF-1 Receptors: Relation to Stress-Induced Sensitization (2010) (106)
GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. (2001) (105)
Rat melanin-concentrating hormone stimulates adrenocorticotropin secretion: evidence for a site of action in brain regions protected by the blood-brain barrier. (1992) (105)
Cocaine- and amphetamine-regulated transcript activates the hypothalamic-pituitary-adrenal axis through a corticotropin-releasing factor receptor-dependent mechanism. (2004) (105)
Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. (1992) (104)
Is gastrin releasing peptide mammalian bombesin? (1980) (104)
Comparison of the biologic actions of corticotropin-releasing factor and sauvagine (1982) (104)
Urocortins and the regulation of gastrointestinal motor function and visceral pain (2004) (101)
Oxytocin potentiates the ACTH-releasing activity of CRF(41) but not vasopressin. (1984) (101)
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. (2008) (100)
SUPPRESSION OF PANCREATIC ENDOCRINE TUMOUR SECRETION BY LONG-ACTING SOMATOSTATIN ANALOGUE (1979) (100)
Isolation and characterization of somatostatin from pigeon pancreas. (1979) (99)
The effect of bombesin and related peptides on prolactin and growth hormone secretion in the rat. (1978) (99)
Actions of bombesin, thyrotropin releasing factor, prostaglandin E2 and naloxone on thermoregulation in the rat. (1977) (99)
Arginine vasopressin and a vasopressin antagonist peptide: Opposite effects on extinction of active avoidance in rats (1981) (99)
Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist. (2007) (98)
Anxiolytic activity of NPY receptor agonists in the conflict test (1997) (98)
A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. (2005) (96)
The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man. (1981) (96)
Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs (2005) (96)
Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. (1997) (96)
Somatostatin-28: selective action on the pancreatic beta-cell and brain. (1981) (96)
Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2. (2001) (95)
Evidence for a physiological role of gonadotropin-releasing hormone (GnRH) or GnRH-like material in the ovary. (1985) (94)
Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies. (1994) (93)
Neurotensin analogues. Structure--activity relationships. (1977) (93)
An O-glycosylated neuroexcitatory conus peptide. (1998) (92)
Stimulation of growth hormone (GH) and somatomedin C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumor GH-releasing factor. (1984) (92)
Somatostatin: analogs with selected biological activities. (1977) (92)
Corticotropin-releasing factor receptors in rat pituitary gland: autoradiographic localization (1984) (91)
Delayed Satiety-Like Actions and Altered Feeding Microstructure by a Selective Type 2 Corticotropin-Releasing Factor Agonist in Rats: Intra-Hypothalamic Urocortin 3 Administration Reduces Food Intake by Prolonging the Post-Meal Interval (2007) (91)
Somatostatin. Total solid phase synthesis. (1974) (90)
Definition of the M-conotoxin superfamily: characterization of novel peptides from molluscivorous Conus venoms. (2005) (89)
Novel excitatory Conus peptides define a new conotoxin superfamily (2003) (89)
An inhibitory effects of interleukin-1a on basal gonadotropin release in the ovariectomized rhesus monkey: reversal by a corticotropin-releasing factor antagonist. (1991) (89)
SST3-selective potent peptidic somatostatin receptor antagonists. (2000) (87)
Induction of hot flashes in premenopausal women treated with a long-acting GnRH agonist. (1983) (87)
Mice are insensitive to the antitesticular effects of luteinizing hormone-releasing hormone agonists. (1983) (87)
Conantokin-G: A novel peptide antagonist to the N-methyl-d-aspartic acid (NMDA) receptor (1990) (86)
Isolation and characterization of somatostatin from anglerfish pancreatic islet. (1979) (85)
Development of a selective agonist at the somatostatin receptor subtype sstr1. (1996) (85)
Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. (1987) (85)
Synthetic peptides used to locate the alpha-bungarotoxin binding site and immunogenic regions on alpha subunits of the nicotinic acetylcholine receptor. (1987) (84)
Human Urocortin II, a Selective Agonist for the Type 2 Corticotropin-Releasing Factor Receptor, Decreases Feeding and Drinking in the Rat (2003) (84)
In vitro and in vivo ACTH-releasing activity of ovine CRF, sauvagine and urotensin I (1983) (82)
Somatostatin: central nervous system actions on glucoregulation. (1979) (82)
Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test (2004) (81)
Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat (2002) (81)
NEUROTENSIN ANALOGS. STRUCTURE-ACTIVITY RELATIONSHIPS (1978) (80)
Behavioral Effects of Central Administration of The Novel CRF Antagonist Astressin in Rats (2000) (79)
Alanine series of ovine corticotropin releasing factor (oCRF): a structure-activity relationship study. (1992) (79)
Neuroendocrinology of the human placenta (1990) (78)
A noncompetitive peptide inhibitor of the nicotinic acetylcholine receptor from Conus purpurascens venom. (1997) (78)
Effects of alpha-flupenthixol and naloxone on CRF-induced locomotor activation. (1984) (78)
Synthesis and relative potencies of new constrained CRF antagonists. (1993) (77)
Critical role of the hypothalamic pituitary adrenal axis in amphetamine-induced sensitization of behavior. (1990) (77)
Central CRF inhibits gastric emptying of a nutrient solid meal in rats: the role of CRF2receptors. (1998) (77)
Conotoxin MI. Disulfide bonding and conformational states. (1983) (77)
Isolation and characterization of hypothalamic growth-hormone releasing factor from common carp, Cyprinus carpio. (1992) (77)
Template-Assembled Synthetic Proteins Designed To Adopt a Globular, Four-Helix Bundle Conformation Form Ionic Channels in Lipid Bilayers (1993) (76)
Specific high affinity binding sites for somatostatin-28 on pancreatic beta-cells: differences with brain somatostatin receptors. (1982) (76)
Central nervous system inhibition of gastric secretion in the rat by gastrin-releasing peptide, a mammalian bombesin. (1981) (75)
Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man. (1985) (75)
Expression, Purification, and Characterization of a Soluble Form of the First Extracellular Domain of the Human Type 1 Corticotropin Releasing Factor Receptor* (2001) (75)
Receptor for calcitonin gene-related peptide: binding to exocrine pancreas mediates biological actions. (1985) (74)
Growth hormone release in response to human pancreatic tumor growth hormone-releasing hormone-40 in children with short stature. (1984) (74)
Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1‐A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats (2007) (73)
Solid‐phase synthesis of somatostatin and glucagon‐selective analogs in gram quantities (1978) (73)
Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction. (2000) (72)
Growth hormone-releasing factor stimulates pancreatic enzyme secretion. (1984) (72)
Characterization of endothelin secretion by vascular endothelial cells. (1990) (72)
Peripheral urocortin delays gastric emptying: role of CRF receptor 2. (1999) (71)
In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. (2000) (71)
Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation. (1984) (71)
Somatostatin receptor gene expression in neuroblastoma (2000) (70)
Inhibition of gastric acid secretion in rats and in dogs by corticotropin-releasing factor. (1984) (70)
A reinvestigation of the Gn-RH (gonadotrophin-releasing hormone) systems in the goldfish brain using antibodies to salmon Gn-RH (2004) (70)
Central nervous system actions of calcitonin gene-related peptide on gastric acid secretion in the rat. (1985) (70)
Abdominal surgery-induced delayed gastric emptying in rats: role of CRF and sensory neurons. (1992) (69)
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. (2010) (69)
Tunicate gonadotropin-releasing hormone (GnRH) peptides selectively activate Ciona intestinalis GnRH receptors and the green monkey type II GnRH receptor. (2005) (69)
ACTH-releasing activity of urotensin I and ovine CRF: Interactions with arginine vasotocin, isotocin and arginine vasopressin (1985) (69)
In vitro responses of rainbow trout (Oncorhynchus mykiss) somatotrophs to carp growth hormone-releasing factor (GRF) and somatostatin. (1990) (68)
Antireproductive effects of a potent gonadotropin-releasing hormone antagonist in the male rat. (1980) (68)
Chronic Cocaine Administration Switches Corticotropin-Releasing Factor2 Receptor-Mediated Depression to Facilitation of Glutamatergic Transmission in the Lateral Septum (2005) (67)
Oxytocin mediates the hypothalamic action of vasoactive intestinal peptide to stimulate prolactin secretion. (1989) (67)
Assay of corticotropin releasing factor. (1983) (67)
Immunohistological localization of growth hormone-releasing hormone in human tumors. (1985) (67)
Behavioral activation by CRF: evidence for the involvement of the ventral forebrain. (1987) (67)
Calcitonin gene related peptide inhibits basal, pentagastrin, histamine, and bethanecol stimulated gastric acid secretion. (1985) (67)
Total solid-phase synthesis of porcine gut gastrin releasing peptide (GRP), a mammalian bombesin (1981) (66)
Pituitary binding sites for ( 3 H)-labelled luteinizing hormone releasing factor (LRF). (1973) (66)
The dynamics of gonadotropin inhibition in women induced by an antagonistic analog of gonadotropin-releasing hormone. (1983) (66)
Binding sites for calcitonin gene-related peptide in distinct areas of rat brain (1985) (65)
Differential antagonist activity of alpha-helical corticotropin-releasing factor9-41 in three bioassay systems. (1991) (64)
The hormonal actions of corticotropin-releasing factor in sheep: effect of intravenous and intracerebroventricular injection. (1983) (64)
Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat. (1999) (63)
A comparison of the behavioral effects of CRF, sauvagine and urotensin I (1984) (63)
Transmitter release from presynaptic terminals of electric organ: inhibition by the calcium channel antagonist omega Conus toxin (1987) (63)
Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. (1984) (63)
Biological activity of somatostatin and somatostatin analogs on inhibtion of arginine-induced insulin and glucagon release in the rat. (1976) (63)
Corticotropin-releasing factor receptors in human pituitary gland: autoradiographic localization. (1985) (63)
Astressin, a novel and potent CRF antagonist, is neuroprotective in the hippocampus when administered after a seizure (1997) (61)
Synthetic TRF (thyrotropin releasing factor) analogues. II. pGlu-N3imMe-His-Pro-NH2: a synthetic analogue with specific activity greater than that of TRF2. (1971) (61)
Intracisternal injection of CRF antagonist blocks surgical stress-induced inhibition of gastric secretion in the rat (1988) (61)
Common and divergent structural features of a series of corticotropin releasing factor-related peptides. (2007) (61)
Synthesis and hypertensive activity of neuropeptide Y fragments and analogues with modified N- or C-termini or D-substitutions. (1989) (60)
Synthetic thyrotropin-releasing factor analogs. 3. Effect of replacement or modification of histidine residue on biological activity. (1972) (60)
Effect of synthetic ovine corticotropin-releasing factor: prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol. (1983) (59)
Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents. (2011) (59)
A minimized human insulin-receptor-binding motif revealed in a Conus geographus venom insulin (2016) (59)
Degradation of luteinizing hormone - releasing hormone and analogs by adenohypophyseal peptidases. (1981) (59)
Reversed-phase high-performance liquid chromatography of insulins from different species. (1983) (59)
Urocortin is not a significant regulator of intermittent electrofootshock-induced adrenocorticotropin secretion in the intact male rat. (1999) (59)
mu-conotoxin GIIIA, a peptide ligand for muscle sodium channels: chemical synthesis, radiolabeling, and receptor characterization. (1989) (59)
Inhibition of the action of sex steroids by gonadotropin-releasing hormone (GnRH) agonists: a new biological effect. (1981) (58)
Effects of human pancreatic growth hormone-releasing factor-40 on serum growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and somatomedin-C concentrations in normal women throughout the menstrual cycle. (1984) (58)
High affinity binding sites for somatostatin to rat pituitary. (1982) (58)
Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy. (1989) (58)
Expression of CRF1 and CRF2 receptors in human cancers. (2003) (58)
Astressin B, a nonselective corticotropin-releasing hormone receptor antagonist, prevents the inhibitory effect of ghrelin on luteinizing hormone pulse frequency in the ovariectomized rhesus monkey. (2008) (58)
Central CRF inhibits gastric emptying of a nutrient solid meal in rats: the role of CRF2 receptors. (1998) (57)
Human Urocortin 2, a Corticotropin-Releasing Factor (CRF)2 Agonist, and Ovine CRF, a CRF1 Agonist, Differentially Alter Feeding and Motor Activity (2004) (57)
Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats. (1999) (57)
Differential suppression of follicle-stimulating hormone and luteinizing hormone secretion in vivo by a gonadotropin-releasing hormone antagonist. (1985) (57)
Differential regulation of corticotropin-releasing factor receptors in anterior and intermediate lobes of pituitary and in brain following adrenalectomy in rats (1985) (57)
Synthetic luteinizing hormone-releasing factor analogs. Series of short-chain amide LRF homologs converging to the amino terminus. (1973) (56)
Immunoreactivities for antisera to three putative neuropeptides of the rat melanin-concentrating hormone precursor are coexpressed in neurons of the rat lateral dorsal hypothalamus (1992) (56)
Importance of pituitary and brain receptors for corticotrophin-releasing factor in modulating alcohol-induced ACTH secretion in the rat (1996) (56)
Calcitonin gene-related peptide acts within the central nervous system to inhibit gastric acid secretion (1984) (56)
Four functional GnRH receptors in zebrafish: analysis of structure, signaling, synteny and phylogeny. (2008) (55)
Characterization of two neuronal subclasses through constellation pharmacology (2012) (55)
Effects of growth hormone-releasing factor on growth hormone secretion in acromegaly. (1985) (54)
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study (2017) (54)
Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH. (1986) (53)
Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men. (1985) (53)
A Soluble Form of the First Extracellular Domain of Mouse Type 2β Corticotropin-releasing Factor Receptor Reveals Differential Ligand Specificity* (2003) (53)
Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I: circular dichroism and prediction studies. (1983) (53)
Effect of a potent GnRH antagonist and testosterone propionate on mating behavior and fertility in the male rat. (1981) (52)
Conformational studies on somatostatin and analogues. (1977) (52)
Total synthesis and further characterization of the gamma-carboxyglutamate-containing "sleeper" peptide from Conus geographus venom. (1987) (52)
Mast cell binding of neurotensin. II. Molecular conformation of neurotensin involved in the stereospecific binding to mast cell receptor sites. (1977) (52)
Enhanced pelvic responses to stressors in female CRF-overexpressing mice. (2007) (52)
GRF analogs and fragments: Correlation between receptor binding, activity and structure (1991) (52)
Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men. (1986) (51)
Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers (2017) (51)
Characterization of four receptor cDNAs: PAC1, VPAC1, a novel PAC1 and a partial GHRH in zebrafish (2005) (51)
Surface properties of an amphiphilic peptide hormone and of its analog: corticotropin-releasing factor and sauvagine. (1983) (50)
Neuropeptide Y and neuropeptide Y18-36. Structural and biological characterization. (2009) (50)
Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2), 4FDPhe2,D-Trp3,D-Arg6]-GnRH. (1985) (50)
Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. (1994) (50)
Growth hormone-releasing factor stimulation test in depression. (1988) (49)
Activation of brain somatostatin 2 receptors stimulates feeding in mice: Analysis of food intake microstructure (2010) (49)
Brain regulation of gastric acid secretion in rats by neurogastrointestinal peptides (1981) (49)
Bombesin analogs: Effects on thermoregulation and glucose metabolism (1981) (49)
Evaluation of triethylammonium phosphate and formate-acetonitrile mixtures as eluents for high-performance gel permeation chromatography (1980) (48)
Central injection of the stable somatostatin analog ODT8-SST induces a somatostatin2 receptor-mediated orexigenic effect: role of neuropeptide Y and opioid signaling pathways in rats. (2010) (48)
Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. (1983) (48)
Peripheral corticotropin-releasing factor mediates the elevation of plasma IL-6 by immobilization stress in rats. (1998) (48)
Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. (2003) (47)
Identification of Ligand Binding Determinants in the Somatostatin Receptor Subtypes 1 and 2* (1996) (47)
Synthesis of potent heptapeptide analogues of cholecystokinin. (1984) (46)
Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions. (1993) (46)
NOCTURNAL PULSATILE GROWTH HORMONE RELEASING HORMONE TREATMENT IN GROWTH HORMONE DEFICIENCY (1986) (46)
Report and Recommendations 14 October 1987 (1988) (45)
Orientation restrictions of the peptide hormone, thyrotropin-releasing factor, due to intramolecular hydrogen bonding. (1972) (45)
Endogenous hypothalamic somatostatins differentially regulate growth hormone secretion from goldfish pituitary somatotropes in vitro. (2003) (45)
Solid-Phase Synthesis of Peptide Amides on a Polystyrene Support Using Fluorenylmethoxycarbonyl Protecting Groups (1987) (45)
Inhibition of gastric acid secretion by brain peptides in the dog. Role of the autonomic nervous system and gastrin. (1986) (45)
β-lipotropin-β-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression : preliminary studies (1990) (45)
Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. (1995) (44)
Peripheral injection of sauvagine prevents repeated colorectal distension-induced visceral pain in female rats (2005) (44)
Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA. (2011) (44)
Synthetic ovine corticotropin-releasing hormone: simultaneous release of proopiolipomelanocortin peptides in man. (1984) (44)
Synthesis, resolution and characterization of ring substituted phenylalanines and tryptophans. (2009) (44)
Molecular Dynamics and Minimum Energy Conformations of GnRH and Analogs: A Methodology for Computer‐aided Drug Design a (1985) (44)
Intranasal administration of human pancreatic tumor GH-releasing factor-40 stimulates GH release in normal men. (1983) (44)
Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF2 (2002) (44)
Somatostatin analogs. Relative importance of the disulfide bridge and of the Ala-Gly side chain for biological activity. (1975) (43)
Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges. (1997) (43)
Conformational studies on the hypothalamic thyrotropin releasing factor and related compounds by 1H nuclear magnetic resonance spectroscopy (1974) (43)
Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy (2012) (43)
Applications of adenohypophyseal cell cultures to neuroendocrine studies. (1976) (43)
Total chemical synthesis, characterization, and immunological properties of an MHC class I model using the TASP concept for protein de novo design (1992) (42)
Identification of immunoreactive neuropeptide-gamma in human placenta: localization, secretion, and binding sites. (1989) (42)
Somatostatin analogs inhibit somatostatin release. (1979) (42)
The gonadotropin-releasing hormone pituitary receptor interacts with a guanosine triphosphate-binding protein: differential effects of guanyl nucleotides on agonist and antagonist binding. (1989) (42)
Antireproductive effects of a potent GnRH antagonist in the female rat. (1981) (42)
Identification of corticotropin-releasing factor (CRF) target cells and effects of dexamethasone on binding in anterior pituitary using a fluorescent analog of CRF. (1986) (42)
Pharmacology of thyrotropin releasing factor (TRF), luteinizing hormone releasing factor (LRF), and somatostatin. (1977) (42)
High-performance liquid chromatography of amino acids, peptides and proteins. CXXVIII. Effect of D-amino acid substitutions on the reversed-phase high-performance liquid chromatography retention behaviour of neuropeptide Y[18-36] analogues. (1993) (42)
The effect of LHRH antagonist analogs and an antibody to LHRH on mating behavior in female rats (1981) (42)
Three-Dimensional Solution Structure of α-Conotoxin MII, an α3β2 Neuronal Nicotinic Acetylcholine Receptor-Targeted Ligand†,‡ (1997) (41)
Distinction of NPY receptors in vitro and in vivo. I. NPY-(18-36) discriminates NPY receptor subtypes in vitro. (1990) (41)
Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6. (1992) (40)
(Gly 2 )LRF and des-His 2 -LRF. The synthesis, purification, and characterization of two LRF analogues antagonistic to LRF. (1972) (40)
Residues of Corticotropin Releasing Factor-binding Protein (CRF-BP) That Selectively Abrogate Binding to CRF but Not to Urocortin 1* (2008) (40)
Characterization of human anti-luteinizing hormone-releasing hormone (LRH) antibodies in the serum of a patient with isolated gonadotropin deficiency treated with synthetic LRH. (1981) (40)
Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. (1981) (40)
A new cytotoxin specific for the target cells of corticotropin-releasing factor. (1987) (40)
Hormonal Effects of Danazol and Medical Oophorectomy in Endometriosis (1983) (39)
NMR Structure of the First Extracellular Domain of Corticotropin-releasing Factor Receptor 1 (ECD1-CRF-R1) Complexed with a High Affinity Agonist* (2010) (39)
Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist. (2007) (39)
Calcitonin gene-related peptide-induced selective inhibition of gastric acid secretion in dogs. (1986) (39)
Single point D-substituted corticotropin-releasing factor analogues: effects on potency and physicochemical characteristics. (1993) (39)
Corticotropin-Releasing Hormone Antagonists, Astressin B and Antalarmin: Differing Profiles of Activity in Rhesus Monkeys (2004) (39)
The dependency of bioactive follicle-stimulating hormone secretion on gonadotropin-releasing hormone in hypogonadal and cycling women. (1988) (39)
KappaM-conotoxin RIIIK, structural and functional novelty in a K+ channel antagonist. (2004) (39)
Synthetic corticotropin-releasing factor stimulates secretion of immunoreactive β-endorphin/β-lipotropin and ACTH by human fetal pituitaries in vitro (1983) (38)
[Molecular structure of the hypothalamic factor (LRF) of ovine origin monitoring the secretion of pituitary gonadotropic hormone of luteinization (LH)]. (1971) (38)
Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition. (1991) (38)
TRH-induced vagal stimulation of duodenal HCO-3 mediated by VIP and muscarinic pathways. (1989) (38)
Synthetic human pancreatic growth hormone releasing factor (GRF) stimulates growth hormone secretion in the domestic fowl (Gallus domesticus). (1984) (37)
Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat. (1998) (37)
Abdominal surgery inhibits circulating acyl ghrelin and ghrelin-O-acyltransferase levels in rats: role of the somatostatin receptor subtype 2. (2011) (37)
Effect of a long-acting octapeptide analogue of somatostatin on growth hormone and pancreatic and gastrointestinal hormones in man. (1981) (36)
Chronic effects of [D-Trp6,Pro9-NEt]luteinizing hormone-releasing factor on reproductive processes in the male rat. (1979) (36)
Selective central activation of somatostatin receptor 2 increases food intake, grooming behavior and rectal temperature in rats. (2010) (36)
An endogenous ligand of the brain σ/PCP receptor antagonizes NMDA-induced neurotransmitter release (1987) (36)
Effects of Synthetic Corticotropin-Releasing Factor and Dopamine on the Release of Immunoreactive β-Endorphin/β-Lipotropin and α-Melanocyte-Stimulating Hormone from Human Fetal Pituitaries in Vitro* (1982) (35)
Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass. (1995) (35)
Calcitonin COOH-terminal cleavage peptide as a model for identification of novel neuropeptides predicted by recombinant DNA analysis. (1982) (35)
αA-Conotoxin OIVA defines a new αA-conotoxin subfamily of nicotinic acetylcholine receptor inhibitors (2004) (35)
Facilitation of sexual receptivity in the female rat by a fragment of the LHRH decapeptide, Ac-LHRH. (1983) (35)
Using Monoclonal Antibodies to Determine the Structures of Acetylcholine Receptors from Electric Organs, Muscles, and Neurons a (1987) (34)
Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis. (1996) (34)
Intravenous urocortin II decreases blood pressure through CRF2 receptor in rats (2003) (34)
Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. (2009) (34)
Conformational analysis of a highly potent, constrained gonadotropin-releasing hormone antagonist. 1. Nuclear magnetic resonance (1992) (33)
Differential suppression of FSH and LH secretion by follicular fluid in the presence or absence of GnRH. (1984) (33)
Treatment with conotoxin, an ‘N-type’ calcium channel blocker, in neuronal hypoxic-ischemic injury (1990) (33)
Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). (2001) (33)
Biological actions of human and rat calcitonin and calcitonin gene-related peptide (1985) (33)
Nuclear magnetic resonance analysis and conformational characterization of a cyclic decapeptide antagonist of gonadotropin-releasing hormone. (1987) (32)
[28] Assay of growth hormone-releasing factor (1986) (32)
Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues. (1993) (32)
Design of potent cyclic gonadotropin releasing hormone antagonists. (1988) (31)
Immediate and Sustained Blood Pressure Lowering by Urocortin 2: A Novel Approach to Antihypertensive Therapy? (2009) (31)
Neurophysiological effects of intracerebroventricular administration of urocortin (1999) (31)
Interleukin 1 prevents loss of corticotropic responsiveness to beta-adrenergic stimulation in vitro. (1988) (31)
Sequence analysis of rat hypothalamic corticotropin-releasing factor with the o-phthalaldehyde strategy. (1983) (30)
Central administration of pan‐somatostatin agonist ODT8‐SST prevents abdominal surgery‐induced inhibition of circulating ghrelin, food intake and gastric emptying in rats (2011) (30)
Identification and characterization of a type five-like somatostatin receptor in goldfish pituitary (2002) (30)
Definition and characterization of the short alphaA-conotoxins: a single residue determines dissociation kinetics from the fetal muscle nicotinic acetylcholine receptor. (2006) (30)
PYY‐preferring receptor in the dorsal vagal complex and its involvement in PYY stimulation of gastric acid secretion in rats (1998) (30)
A Uniquely Selective Inhibitor of the Mammalian Fetal Neuromuscular Nicotinic Acetylcholine Receptor (2005) (30)
Pituitary responses to synthetic corticotropin-releasing hormone: absence of modulatory effects by estrogen and progestin. (1987) (29)
Peripheral activation of corticotropin-releasing factor receptor 2 inhibits food intake and alters meal structures in mice (2011) (29)
A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. (1998) (29)
CRF Receptor Antagonist Astressin-B Reverses and Prevents Alopecia in CRF Over-Expressing Mice (2011) (28)
Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. (1994) (28)
Comparison of the effect of several gonadotropin releasing hormone antagonists on luteinizing hormone secretion, receptor binding and ovulation. (1983) (28)
Identification of a Novel Pharmacophore for Peptide Toxins Interacting with K+ Channels* (2005) (28)
A novel corticotropin‐releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress‐induced heart disease (2009) (28)
Corticotropin-releasing factor peptide antagonists: Design, characterization and potential clinical relevance (2014) (28)
Effect of an LHRH agonist on pituitary and testicular function in rhesus monkeys. (1984) (28)
Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity. (2008) (27)
Acylated des-(Ala1-Gly2)-somatostatin analogs: prolonged inhibition of growth hormone secretion. (1974) (27)
Effects of Low Dose Ovine Corticotropin-Releasing Hormone in Humans: Endocrine Relationships and β: Endorphin/β-Lipotropin Responses* (1988) (27)
Design of Peptide Analogs: Theoretical Simulation of Conformation, Energetics, and Dynamics (1984) (27)
Inhibition of CRF- and urotensin I-stimulated ACTH release from goldfish pituitary cell columns by the CRF analogue α-helical CRF-(9–41) (1987) (27)
Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease. (1985) (26)
Somatostatin receptor 1 selective analogues: 4. Three-dimensional consensus structure by NMR. (2005) (26)
Novel gonadotropin-releasing hormone antagonists: peptides incorporating modified N omega-cyanoguanidino moieties. (1991) (26)
High-performance liquid chromatographic purification of peptide hormones: ovine hypothalamic amunine (corticotropin releasing factor). (1982) (26)
Pharmacological fractionation of tetrodotoxin‐sensitive sodium currents in rat dorsal root ganglion neurons by μ‐conotoxins (2013) (26)
Peptides and regulation of body temperature. (1981) (26)
Effect of gonadotropin-releasing hormone antagonists on serum follicle-stimulating hormone and luteinizing hormone under conditions of singular follicle-stimulating hormone secretion. (1985) (26)
Characterization of growth hormone-releasing hormone receptors in pituitary adenomas from patients with acromegaly. (1988) (26)
Synthesis and conformations of hypothalamic hormone releasing factors: two QRF-analogues containing backbone N-methyl groups (1975) (26)
Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration. (1988) (25)
Conformational analysis of a highly potent, constrained gonadotropin-releasing hormone antagonist. 2. Molecular dynamics simulations (1992) (25)
Release of gonadotropins by oral administration of synthetic LRF or a tripeptide fragment of LRF. (1972) (25)
Peptides from Conus Venoms which Affect Ca++ Entry into Neurons (1990) (25)
Direct inhibition of testicular steroidogenesis and gonadotrophin receptor levels by [(imBzl)-D-His6, Pro9-NEt]GnRH and [D-Trp6, Pro9-NEt]GnRH, potent agonists of GnRH. (1982) (25)
Effects of gonadotropin releasing hormone agonists and antagonists on reproductive functions. (1983) (25)
Structure-activity relationships of somatostatin analogs in the rabbit ileum and the rat colon. (1983) (25)
Gonadotropins and testosterone escape from suppression during prolonged luteinizing hormone-releasing hormone antagonist administration in normal men. (1987) (24)
Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone. (1986) (24)
Growth-hormone-releasing factor. (1983) (24)
Somatostatin analogs with selected biologic activities. (1976) (24)
Newly-identified receptors for peptide histidine-isoleucine and GHRH-like peptide in zebrafish help to elucidate the mammalian secretin superfamily. (2008) (24)
Intracisternal injection of somatostatin receptor 5-preferring agonists induces a vagal cholinergic stimulation of gastric emptying in rats. (2000) (24)
Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling. (2000) (24)
Antagonism of central growth hormone-releasing factor activity selectively attenuates dark-onset feeding in rats (1991) (23)
Human pancreatic growth hormone releasing factor (hpGRF-1-40) stimulates GH release in the ovine fetus. (1984) (23)
Separation of neuropeptide Y diastereomers by high-performance liquid chromatography and capillary zone electrophoresis. (1993) (23)
Assignment of the 270 MHz nuclear magnetic resonance spectrum of somatostatin in water. (1980) (23)
The antiandrogenic action of gonadotropin-releasing hormone and its agonists on the mouse kidney. (1982) (23)
Synthetic luteinizing hormone releasing factor. Short chain analogs. (1974) (23)
NMR structure determination of a novel conotoxin, [Pro 7,13] alpha A-conotoxin PIVA. (1997) (23)
The effect of intravenous, subcutaneous, and intranasal GH‐RH analog, [Nle27]GHRH(1–29)‐NH2, on growth hormone secretion in normal men: Dose‐response relationships (1986) (23)
Heterogeneity of sperm density profiles following 20-week therapy with high-dose LHRH analog plus testosterone. (1984) (22)
Corticotropin-releasing factor inhibits gastric emptying in dogs: Studies on its mechanism of action (1987) (22)
Centrally administered hypothalamic growth hormone-releasing factor stimulates food intake in free-feeding rats (1988) (22)
Control of Anterior Pituitary Hormone Secretion (1974) (22)
Effect of GnRH antagonist, [Ac-delta 3Pro1, pFDPhe2, DTrp3,6] GnRH, on pulsatile gonadotrop in secretion in the castrate male primate. (1983) (22)
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity. (2008) (22)
Conformational analysis of a highly potent dicyclic gonadotropin-releasing hormone antagonist by nuclear magnetic resonance and molecular dynamics. (1993) (22)
Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. (2003) (22)
Use of somatostatin and somatostatin analogs in a patient with a glucagonoma. (1981) (21)
Dose relationship between GnRH antagonists and pituitary suppression. (1996) (21)
Analysis of synthetic peptides by capillary zone electrophoresis in organic/aqueous buffers. (2009) (21)
Effects of Mammalian and Salmon Gonadotropin-Releaslng Hormones and Analogues on Plasma Gonadotropin Levels and Ovulation in Coho Salmon (Oncorhynchus kisutch) (1987) (20)
Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes (2013) (20)
Distinction of NPY receptors in vitro and in vivo. II. Differential effects of NPY and NPY-(18-36). (1990) (19)
Betidamino acid scan of the GnRH antagonist acyline. (1997) (19)
Effect of synthetic ovine corticotropin-releasing factor: Prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol (1984) (19)
Anxiolytic-Like Effects of Antisauvagine-30 in Mice Are Not Mediated by CRF2 Receptors (2013) (19)
LHRH analogs as antiovulatory agents (1984) (19)
Pituitary somatostatin receptors: dissociation at the pituitary level of receptor affinity and biological activity for selective somatostatin analogs (1982) (19)
Proposed tertiary structure for the hypothalamic thyrotropin-releasing factor. (1973) (19)
Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. (2003) (19)
Design of potent dicyclic (4-10/5-8) gonadotropin releasing hormone (GnRH) antagonists. (2000) (19)
Α- and β-subunit composition of voltage-gated sodium channels investigated with μ-conotoxins and the recently discovered μO§-conotoxin GVIIJ. (2015) (19)
Studies of the inhibin family of hormones: a review. (1987) (18)
Reversal by NPY, PYY and 3–36 molecular forms of NPY and PYY of intracisternal CRF‐induced inhibition of gastric acid secretion in rats (1996) (18)
Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. (1998) (18)
Betidamino acids: versatile and constrained scaffolds for drug discovery. (1996) (18)
The effect of 'Astressin', a novel antagonist of corticotropin releasing hormone (CRH), on CRH-induced seizures in the infant rat: comparison with two other antagonists. (1996) (18)
GnRH analogs: structure-activity relationships. (1981) (18)
Peripheral urocortin delays gastric emptying: role of CRF receptor 2. (1999) (18)
Guinea Pig Gonadotropin-Releasing Hormone: Expression Pattern, Characterization and Biological Activity in Rodents (2002) (18)
Verification of both the sequence and conformational specificity of neurotensin in binding to mast cells. (1977) (18)
Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. (2003) (18)
Mammalian neuronal sodium channel blocker μ-conotoxin BuIIIB has a structured N-terminus that influences potency. (2013) (17)
Somatostatin analogs as glucagon suppressants in diabetes. (1978) (17)
Direct sequence determination of ovine luteinizing hormone releasing factor by mass spectrometry. (1973) (17)
Somatostatin Receptor 1 Selective Analogues: 2. Nα-Methylated Scan† (2005) (17)
Conformation of somatostatin using scalar coupling constants from 270 and 600 MHz simulated proton magnetic resonance spectra. (1983) (17)
Analogues of luteinizing hormone releasing factor modified at positions 2, 6, and 10. (1976) (17)
Species differences in the sensitivity to the antitesticular effects of [Ac-D-NAL(2)1, 4FD-Phe2, D-Trp3,D-Arg6]-LHRH, a potent LHRH antagonist. (1984) (17)
Clinical studies with GHRH in man. (1986) (17)
Synthesis of human CCK26-33 and CCK-33 related analogues on 2,4-DMBHA and TMBHA. (1993) (17)
Nature of ligand affinity and dimerization of corticotrophin-releasing factor-binding protein may be detected by circular dichroism. (1996) (17)
Evidence for a common neural mechanism mediating growth hormone-releasing factor-induced and somatostatin-induced feeding. (1993) (17)
Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in rats (2010) (16)
Identification of high-potency neuropeptide Y analogues through systematic lactamization. (1997) (16)
Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges. (1998) (16)
Pharmacology of gonadotropin releasing hormone: a model regulatory peptide. (1981) (16)
Biochemical characterization of Drosophilaγ‐glutamyl carboxylase and its role in fly development (2006) (15)
Peptides : chemistry, structure and biology : proceedings of the eleventh American Peptide Symposium, July 9-14, 1989, La Jolla, California, U.S.A. (1990) (15)
Neurobiological actions of cysteamine. (1985) (15)
Design of monocyclic (1-3) and dicyclic (1-3/4-10) gonadotropin releasing hormone (GnRH) antagonists. (2000) (15)
Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands. (1992) (15)
Central somatostatin receptor 1 activation reverses acute stress‐related alterations of gastric and colonic motor function in mice (2011) (15)
DOSE RESPONSE OF PLASMA ADRENOCORTICOTROPIN AND CORTISOL (1983) (15)
Clinical studies with synthetic ovine corticotropin-releasing factor. (1985) (15)
Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin. (1999) (15)
Growth hormone response to growth hormone releasing factor in Alzheimer's disease. (1989) (15)
Luteinizing hormone releasing factor. The total solid-phase synthesis on a benzhydrylamine polymer. (1972) (15)
Astressin B, a corticotropin-releasing hormone receptor antagonist, accelerates the return to normal luteal function after an inflammatory-like stress challenge in the rhesus monkey. (2007) (14)
Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. (2005) (14)
Somatoliberinoma: morphologic characteristics. (1984) (14)
Central actions of somatostatin-28 and oligosomatostatin agonists to prevent components of the endocrine, autonomic and visceral responses to stress through interaction with different somatostatin receptor subtypes. (2012) (14)
Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man (1987) (14)
Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives. (2007) (14)
Distribution of corticotropin‐releasing factor (CRF) receptor binding in the mouse brain using a new, high‐affinity radioligand, [125I]‐PD‐Sauvagine (2017) (14)
CHARACTERIZATION OF MAMMALIAN MELANIN CONCENTRATING HORMONES AND THEIR PRECURSORS (1989) (14)
Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR. (2003) (14)
Design of potent dicyclic (1-5/4-10) gonadotropin releasing hormone (GnRH) antagonists. (2000) (14)
Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. (2006) (14)
[Preliminary observations on the mechanism of action of somatostatin, a hypothalamic factor inhibiting the secretion of growth hormone]. (1972) (13)
Increased ghrelin sensitivity and calorie consumption in subordinate monkeys is affected by short-term astressin B administration (2010) (13)
Cycloadditions to Derivatives of Methylenequadricyclane and of Quadricyclanone (Bishomocyclobutadiene) (1967) (13)
Conformational analysis of a potent SSTR3‐selective somatostatin analogue by NMR in water solution (2006) (13)
Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges. (1998) (13)
Study of the secondary structure of the luteinizing hormone releasing factor using intramolecular charge transfer complexes. (1977) (13)
AlphaA-Conotoxin OIVA defines a new alphaA-conotoxin subfamily of nicotinic acetylcholine receptor inhibitors. (2004) (13)
Novel gonadotropin‐releasing hormone antagonists with substitutions at position 5 (2005) (12)
Structural requirements for neuropeptide Y18-36-evoked hypotension: a systematic study. (1992) (12)
Concomitant release of FSH and LH induced by native and synthetic LRF. (1973) (12)
Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. (2005) (12)
CRF receptors in the rodent and human cardiovascular systems: Species differences (2006) (12)
Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior. (2014) (12)
Peptides. Chemistry and Biology: Proceedings of the American Peptide Symposium (12th) Held in Cambridge, Massachusetts on 16-21 June 1991. (1992) (12)
Effect of the LRF-antagonist [D-pGlu1, D-Phe2, D-Trp3,6]-LRF on pregnancy in the rat. (1979) (12)
Peptide N-alkylamides by solid phase synthesis. (2009) (12)
Somatostatin: central nervous system (CNS) action on glucoregulation. (1978) (12)
Norcystine, a new tool for the study of the structure-activity relationship of peptides. (2006) (12)
Inhibition of estradiol-induced gonadotropin release in ovariectomized rhesus macaques by a gonadotropin-releasing hormone antagonist. (1986) (11)
LHRH in hypogonadotropic hypogonadism. (1981) (11)
Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR. (2008) (11)
Conotoxins : targeted peptide ligands from snail venoms (1990) (11)
Expression and Functional Characterization of Membrane-Integrated Mammalian Corticotropin Releasing Factor Receptors 1 and 2 in Escherichia coli (2014) (11)
Biological assays utilized to characterize LHRH and its analogs (1984) (11)
Colocalization of urocortin and neuronal nitric oxide synthase in the hypothalamus and Edinger‐Westphal nucleus of the rat (2004) (11)
First clinical evaluation of somatostatin receptor antagonist imaging (2010) (11)
(R)-tert-Butoxycarbonylamino-fluorenylmethoxycarbonyl-glycine from (S)-benzyloxycarbonyl-serine or from papain resolution of the corresponding amide or methyl ester. (2000) (11)
Biotinylation of a bombesin/gastrin-releasing peptide analogue for use as a receptor probe (1991) (11)
Beta-lipotropin-beta-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression. Preliminary studies. (1990) (11)
A Novel Conformation in a Highly Potent, Constrained Gonadotropin-Releasing Hormone Antagonist (1996) (10)
Conformational studies of somatostatin and selected analogues by Raman spectroscopy. (2009) (10)
Solid Phase Synthesis of Amunine (CRF), Sauvagine and Two Urotensin I (1983) (10)
Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers (2011) (10)
N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function. (2011) (10)
Biological potency of synthetic somatostatin in the oxidized and reduced form on the inhibition of secretion of growth hormone. (1974) (9)
Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products. (2013) (9)
Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions. (1999) (9)
Angiotensin II. Synthesis and biological activity of 6-(1-methylhistidine) and 6-(3-methylhistidine) analogs. (1973) (9)
Gonadotropin releasing hormone antagonists: novel structures incorporating N omega-cyano modified guanidine moieties. (1991) (9)
Rat melanin-concentrating hormone stimulates adrenocorticotropin secretion (1992) (9)
Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice (2015) (9)
Synthesis, in vivo and in vitro biological activity of novel azaline B analogs. (2005) (8)
Effects of human pancreatic and rat hypothalamic growth hormone-releasing factors on growth hormone secretion in steers☆☆☆ (1986) (8)
Assay of growth hormone-releasing factor. (1986) (8)
Peptides : chemistry and biology : proceedings of the twelfth American Peptide Symposium, June 16-21, 1991, Cambridge, Massachusetts, U.S.A. (1992) (8)
Use of carboethoxysulfenyl chloride for disulfide bond formation. (1986) (8)
General method for incorporation of modified N.omega.-cyanoguanidino moieties on selected amino functions during solid-phase peptide synthesis (1990) (8)
Total synthesis, purification, and characterization of human [Phe(p-CH2SO3Na)52, Nle32,53,56, Nal55]-CCK20–58, [Tyr52, Nle32,53,56,Nal55]-CCK-58, and [Phe(p-CH2SO3Na)52, Nle32,53,56, Nal55]-CCK-58 (1993) (8)
An expanded nomenclature scheme for labeling peptide fragmentations and its use with 'AMASS', a computer program for generating all possible fragment ion structures from known precursors. (1993) (8)
Effects of the (imBzl)D-His6, Des-Gly analog of GnRH on gonadotropin and estradiol secretion in normal women. (1984) (8)
MS based scanning methodologies applied to Conus venom (1995) (8)
Rat corticostatin R4: Synthesis, disulfide bridge assignment, and in vivo activity (1995) (8)
New specific long-acting somatostatin analogues in the treatment of pancreatic endocrine tumours (1978) (7)
Gastrin releasing peptide (GRP): Central nervous system (CNS) action to inhibit gastric secretion in rats (1980) (7)
Differential Antagonist Activity of a-Helical Corticotropin-Releasing Factor 9 _ 4 i in Three Bioassay Systems* (1991) (7)
Chemistry of hypothalamic releasing factors. (1973) (7)
Micro-Sequence Analysis of Ovine Hypothalamic Corticotropin Releasing Factor (1982) (7)
Flow cytometric separation of gonadotrophs from dispersed rat pituitaries using a fluorescent GNRH antagonist (1983) (7)
Effect of a potent gonadotropin releasing hormone antagonist on pulsatile testosterone and gonadotropin secretion in the male nonhuman primate. (1984) (7)
Chronic injection of pansomatostatin agonist ODT8-SST differentially modulates food intake and decreases body weight gain in lean and diet-induced obese rats (2011) (7)
Development of antibody to growth hormone-releasing factor. (1985) (7)
Astressin-amide and astressin-acid are structurally different in dimethylsulfoxide. (2007) (6)
Synthesis of a cyclic analog of the luteinizing hormone releasing factor: LRF (1977) (6)
Characterization of a Pachymedusa dacnicolor–Sauvagine Analog as a New High-Affinity Radioligand for Corticotropin-Releasing Factor Receptor Studies (2015) (6)
Effects of intracoronary infusion of the vasoactive intestinal peptide antagonist [4Cl-D-Phe6-Leu17]VIP in the awake dog (1991) (6)
DESIGN, COMPUTER DERIVED STRUCTURE AND BIOLOGICAL ACTIVITY OF THREE BICYCLIC GONADOTROPIN RELEASING HORMONE (GnRH) ANTAGONISTS (1990) (6)
Stimulation of in-vivo growth hormone secretion in young chickens by rat hypothalamic growth hormone-releasing factor and synthetic analogues. (1986) (6)
On the biological activities of the synthetic tetrapeptide pyroglutamyl-tyrosyl-arginyl-tryptophanyl-amide. (1972) (6)
Assignments of the 270 MHz PMR spectrum of somatostatin using pH titration, synthetic analogs and double resonance difference spectroscopy. (2009) (6)
Potent Long‐Acting Growth Hormone Releasing Factor Analogues 1 a (1988) (6)
Synthesis, purification and characterization of rat histone H2A (1-53)-NH2 (1991) (6)
Polypeptides antagonists of the hypothalamic luteinizing hormone releasing factor. (1971) (6)
Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine. (2008) (5)
Single dose responses to the gonadotropin-releasing hormone agonist analogue [(imBz 1)-D-His6,Pro9-NEt]GnRH. (1986) (5)
Isolation and characterization of hypothalamic peptide hormones. (1976) (5)
Variability of the duration of inhibition of growth hormone release by Nalpha-acylated-des-(Ala1-Gly2)-H2somatostatin analogs. (1975) (5)
Three-dimensional solution structure of alpha-conotoxin MII, an alpha3beta2 neuronal nicotinic acetylcholine receptor-targeted ligand. (1997) (5)
Synthesis and theoretical conformational studies of gonadotropin-releasing hormone analogs containing tetrahydroisoquinoline carboxylic acid. (1992) (5)
A 90-Day Subcutaneous Toxicity and Fertility Study of a LHRH Antagonist in Rats (1990) (5)
Growth hormone releasing factor and somatomedin C production: extrahypothalamic localization and possible functional significance. (1986) (5)
Structural Basis for the Inhibition of Voltage-gated Sodium Channels by Conotoxin μO§-GVIIJ* (2015) (5)
Metastable fragmentation of somatostatin-14 (SS-14) and a series of SS-14 analogs formed with liquid secondary ion mass spectrometry: Observation of fragment ions which involve unsymmetric disulfide bridge cleavage concomitant with peptide chain cleavage (1992) (5)
Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. (2005) (5)
Solid-state NMR sequential assignment of the β-endorphin peptide in its amyloid form (2016) (4)
Protective effects of urocortin 2 against caerulein-induced acute pancreatitis (2019) (4)
A 90-day subcutaneous toxicity and fertility study of a LHRH antagonist in rats. (1990) (4)
Polypeptide antagonists of the hypothalamic luteinizing hormone releasing factors. (1973) (4)
Accelerated protocols for solid-phase peptide synthesis at elevated temperature. (1994) (4)
Effects of synthetic corticotropin-releasing factor and dopamine on the release of immunoreactive beta-endorphin/beta-lipotropin and alpha-melanocyte-stimulating hormone from human fetal pituitaries in vitro. (1982) (4)
Identification of new gonadotrophin-releasing hormone partial agonists. (2006) (4)
Peptides Structure and Biology (1990) (4)
4 – RECOVERY OF BIOLOGICAL ACTIVITY, BLOTTING AND SEQUENCE ANALYSIS OF PROTEIN HORMONES AFTER SDS-PAGE1 (1989) (4)
Synthetic corticotropin-releasing factor stimulates secretion of immunoreactive beta-endorphin/beta-lipotropin and ACTH by human fetal pituitaries in vitro. (1983) (4)
SPPS using high temperature (1994) (3)
Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins). (2016) (3)
Partial purification of inhibin from ovine rete testis fluid. (1986) (3)
Therapeutic agents produced by genetic engineering: Quo vadis? The example of growth hormone and its releasing factor. Satellite symposium. Toulouse-Labège, May 29-30, 1985. (1986) (3)
Lack of effect of native or synthetic LRF on secretion of prolactin in vitro. (1973) (3)
SYNTHETIC LUTEINIZING HORMONE RELEASING FACTOR, SHORT CHAIN ANALOGS (1974) (3)
STRUCTURE/FUNCTION CHARACTERIZATION OF μ -CONOTOXIN KIIIA, AN ANALGESIC, NEARLY IRREVERSIBLE BLOCKER OF NEURONAL MAMMALIAN SODIUM CHANNELS* (2007) (3)
The dependency of bioactive follicle-stimulating hormone secretion on gonadotropin-releasing hormone in hypogonadal and cycling women (1989) (3)
The Physiology of Human Growth: Growth hormone and growth hormone releasing hormone (1989) (3)
[Solid-phase total synthesis of a tetradecapeptide having the chemical and biological properties of somatostatine]. (1973) (3)
Synthesis, Resolution, and Characterization of Ring Substituted Phenylalanines and Tryptophans. (1988) (3)
Analogs of thyrotropin-releasing hormone using an aminoglycine-based template (1998) (3)
Conformational analysis of somatostatin and selected analogs in oriented polyoxyethylene by infrared dichroism (1980) (3)
3D NMR structure of the first extracellular domain of CRFR-2beta, a type B1 G-protein coupled receptor (2004) (3)
NMR analysis and conformational characterization of cyclic antagonists of gonadotropin-releasing hormone (1988) (3)
Probing Acetylcholine Receptors with Monoclonal Antibodies (1986) (3)
Effects of [d-Trp6,Pro9-NEt]-LHRH on reproductive functions in the male rat. (1980) (3)
Effects of low dose ovine corticotropin-releasing hormone in humans: endocrine relationships and beta-endorphin/beta-lipotropin responses. (1988) (3)
Design of Monocyclic (1—3) and Dicyclic (1—3/4—10) Gonadotropin Releasing Hormone (GnRH) Antagonists. (2000) (3)
Large-Scale Synthesis of Gonadotropin-Releasing Hormone Antagonists for Clinical Investigations (1991) (3)
Synthesis and activity of human amylin and analogues (1992) (2)
Human pancreatic tumor GH-releasing factor (2005) (2)
Use of Betidamino Acids in Drug Design (2006) (2)
Solid phase synthesis of acid-sensitive peptide amides (1988) (2)
Gonadotropin-releasing hormone antagonists containing novel amino acids (1994) (2)
Inhibin: measurement and role in the rat. (1987) (2)
Synthesis of protected norcysteines for SPPS compatible with Fmoc-strategy. (2007) (2)
SOMATOSTATIN ANALOGS, RELATIVE IMPORTANCE OF THE DISULFIDE BRIDGE AND OF THE ALA‐GLY SIDE CHAIN FOR BIOLOGICAL ACTIVITY (1975) (2)
A strategy to assign a series of fragment ions: investigation of fragment ions involving peptide side chain and backbone cleavage (1993) (2)
Prospective Clinical Applications of CRF Peptide Antagonists. (2017) (2)
High-Performance Liquid Chromatographic Purification of Peptide Hormones: Ovine Hypothalamic Amunine (Corticotropin Releasing Factor)1 (1983) (2)
Newly-identified receptors for PHI and GHRH-like peptide in zebrafish help to (2008) (2)
Novel, water soluble and long acting GnRH antagonists (2002) (2)
TOTAL SYNTHESIS OF THE HYPOTHALAMIC THYROTROPIN RELEASING FACTOR. (1975) (2)
Conformational Analysis of a Highly Potent, Constrained Gonadotropin‐ Releasing Hormone Antagonist. Part 2. Molecular Dynamics Simulations. (1992) (2)
Human Urocortin 2 (2008) (2)
Chemical, Anatomical, and Physiological Studies on Human Pancreatic and Rat Hypothalamic Growth Hormone-Releasing Factor (1986) (2)
Synthesis of human CCK-58-related analogs (1994) (1)
Probing the GnRH receptor with linear and cyclic analogs (1993) (1)
Competitive antagonists of the corticotropin releasing factor (CRF) scanned with a i-(i+3) Glu Lys Bridge (2002) (1)
N-Methyl Scan of a sst1-Selective Somatostatin (SRIF) Analog (2001) (1)
First clinical evidence that radiolabeled somatostatin receptor antagonist may be preferable to agonists for the treatment of neuroendocrine tumors (2012) (1)
Defining the active conformation of gonadotropin releasing hormone (GnRH) through design and conformational analysis of constrained GnRH analogs (1994) (1)
Postoperative delay in gastric emptying is prevented by intracisternal injection of CRF antagonist in the rat (1990) (1)
TYROSYLATED ANALOGUES OF SOMATOSTATIN (1976) (1)
A New Route to the Tetracyclo[3.2.0.02,704,6]‐heptan‐3‐one System (1967) (1)
SYNTHESIS OF POTENT HEPTAPEPTIDE ANALOGS OF CHOLECYSTOKININ (1984) (1)
CRF receptor types involved in peripheral urocortin-induced inhibition of food intake and gastric emptying in mice (2000) (1)
Synthesis of a New Cyclic Gonadotropin Releasing Hormone (GnRH) Antagonist. (1988) (1)
[Total synthesis by solid phase of a decapeptide stimulating the secretion of LH and FSH pituitary gonadotropins]. (1971) (1)
Peptides and proteins act as bridges between the immune and the endocrine systems (1992) (1)
Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists (2006) (1)
154 Evaluating the effects of prophylactic antibiotics on intestinal health in pigs given a corticotropin-releasing factor antagonist during weaning and transport (2020) (1)
Peripheral CRF-induced stimulation of colonic transit and inhibition of gastric emptying in rats involve CRFR1 & CRFR2 respectively (2000) (1)
ANALOGUES OF LUTEINIZING HORMONE RELEASING FACTOR MODIFIED AT POSITIONS 2, 6, AND 10 (1976) (1)
Effects of Somatostatin on Flushing and Plasma Gastrointestinal Peptides in the Carcinoid Syndrome (1980) (1)
Conformationally altered fragments of rat GRF: VIP homologs, analogs or both? (1985) (1)
Cytotoxic analog of corticotropin releasing factor crf selectively eliminates crf target cells (1987) (1)
Peripheral CRF stimulates colonic propulsion and inhibits gastric emptying in mice: Differential role of CRF receptor subtypes 1 (CRF-R1) and 2 (CRF-R2) (2001) (1)
Modulation of brain NMDA receptors: common mechanism of sigma/PCP receptors and their exogenous and endogenous ligands. (1986) (1)
Erratum to: Increased ghrelin sensitivity and calorie consumption in subordinate monkeys is affected by short-term astressin B administration (2010) (1)
ATTEMPTS AT THE SYNTHESIS OF FOLLICLE STIMULATING HORMONE RELEASING PROTEIN (FRP) (1987) (1)
Clinical Pharmacology of LHRH Antagonists (1990) (1)
Hormones in Pituitary Secretory Granules Functional Amyloids As Natural Storage of Peptide (2009) (1)
Growth hormone releasing factors stimulate in vitro pancreatic enzyme secretion (1984) (1)
Chemical modulation of regulatory peptides (1985) (1)
Characterization of Betidamino Acid-Containing Somatostatin and Gonadotropin-Releasing Hormone Analogs with Electrospray Mass Spectrometry and Tandem Mass Spectrometry (2001) (1)
CHARACTERIZATION OF RAT HYPOTHALAMIC GROWTH HORMONE AND CORTICOTROPIN RELEASING FACTORS (1983) (1)
Conus Peptides and Biotechnology (1992) (1)
EFFECTS OF GONADOTROPIN RELEASING HORMONE AGONISTS AND ANTAGONISTS ON REPRODUCTIVE FUNCTIONS (1984) (1)
Mo1844 Selective Agonists of Somatostatin Receptors Type 1 or 2 Prevent Visceral Hyperalgesia Induced by Activation of Peripheral CRF1 Receptors in Mice (2012) (0)
LHRH antagonists and non-toxic salts thereof, and pharmaceutical composition containing these (1984) (0)
Gonadotropin-Releasing Hormone Pharmacology: Agonists and Antagonists (2003) (0)
rCRF and similar compounds. (1984) (0)
Subject Index Vol. 50, 1989 (1989) (0)
The receptors (SSTR2) -selective somatostatinantagonister (2007) (0)
Peptides which inhibit the release of gonadotropins by the pituitary gland of mammals and the method for preventing ovulation and / or inhibiting the release of steroids (1984) (0)
Subject Index Vol. 36, 1983 (1983) (0)
Erratum (1975) (0)
Antagonistes de gnrh modifies aux positions 5 et 6 (1998) (0)
Primary structure of corticotropmi-releasing factor from ovine hypothalamus ( micro-sequence analysis / reverse-phase high-pressure liquid chromatography / dansylation / thermolysin / carboxypeptidase Y ) (0)
GnRH antagonists: A synopsis (1992) (0)
Wylie Vale: Neuroendocrine master (2012) (0)
3D NMR structure of ECD1 of mCRF-R2b in complex with Astressin (2007) (0)
Peptides and products containing peptides (1985) (0)
Peptides and compositions containing the peptides (1985) (0)
The effect of D-amino acid substitutions on the interaction of neuropeptide Y-(18–36) analogues with hydrophobic surfaces (1994) (0)
Actions of GRF in Man (1987) (0)
Solution structure of sst1-selective somatostatin (SRIF) analog (2005) (0)
Growth-Hormone-Releasing Factor: Clinical Considerations (1987) (0)
NMR strcutre of sst1-selective somatostatin (SRIF) analog 1 (2005) (0)
Gonadotropin-Releasing Hormone Antagonists : Novel Members of the Azaline (2001) (0)
Antihyperalgesic Effect of Stable Pansomatostatin Agonist, ODT-8 and Selective Somatostatin Type 1 Receptor (SST1) Agonist Injected Intraperitoneally During Colorectal Distension in Mice (2011) (0)
Chromatographic characterization of template assembled synthetic proteins (TASP) and other large peptides using narrow-bore IEC, RPHPLC, CZE and MS analysis (1991) (0)
NMR Structure of the ECD1 of CRF-R1 in complex with a peptide agonist (2010) (0)
Mo1657 Dose-Dependent Antihyperalgesic Effect of Somatostatin (sst) Receptor Agonists in a Rodent Model of Visceral Hypersensitivity Induced by Noxious Colorectal Distension (2012) (0)
Peptides for pharmaceutical treatment of mammals (1984) (0)
Structure-Activity Relationships of Conformationally Restricted Deletion Analogs of Neuropeptide Y, (1992) (0)
GnRH antagonist-vii. (1985) (0)
Introduction: THE STP-3 SAMPLE WORKSHOP (1989) (0)
137 Role of CRF2 Pathway in the Prevention of Stress-Induced Colonic Sensori-Motor Alterations in Mice (2010) (0)
Peptide and the agent containing the peptide for pharmaceutical treatment of mammals (1990) (0)
Gonadal Peptide Hormones Modulating FSH Secretion (1987) (0)
Characterization of Gonadotropin Hormone-Releasing Hormone Analogs (1989) (0)
Design of Potent Dicyclic (4—10/5—8) Gonadotropin Releasing Hormone (GnRH) Antagonists. (2000) (0)
Conformation of a Highly Potent Bicyclic GnRH Antagonist by Combined Molecular Dynamics and Two-Dimensional NMR Analyses, (1992) (0)
SYNTHETIC LUTEINIZING HORMONE RELEASING FACTOR ANALOGS, SERIES OF SHORT-CHAIN AMIDE LRF HOMOLOGS CONVERGING TO THE AMINO TERMINUS (1973) (0)
Are radiolabeled somatostatin receptor antagonists superior to agonists for in vivo tumor targeting (2007) (0)
TWO NEW VASOPRESSIN ANALOGUES CONTAINING AMIDE BOND INSTEAD OF DISULFIDE BRIDGE EXHIBIT SELECTIVE ANTIVASOPRESSOR ACTIVITY (1993) (0)
Peptide that affects the function hypofysekirtlens (1984) (0)
United States Patent ( 19 ) Rivier et al . ( 54 CYCLIC GNRH ANTAGONISTS 75 Inventors : (2017) (0)
Novel approaches to template assembled synthetic proteins (TASP) (1991) (0)
GnRH antagonistic peptide, and pharmaceutically acceptable salts thereof, and pharmaceutical composition containing the peptide (1985) (0)
GnRH antagonists we (1985) (0)
Refined 3D NMR structure of ECD1 of mCRF-R2beta at pH 5 (2007) (0)
Pharmacology of GnRH analogues (1985) (0)
Novel GnRH Antagonists Derived from Degarelix: Exploration of the GnRH Antagonist Pharmacophore (2006) (0)
Human Urocortin 1 (2008) (0)
The peptides which affect function hypofysekirtlens (1984) (0)
Melanin Concentrating Hormone and dns expremieren these (1990) (0)
T1808 Increased Food Intake Associated with Decreased Body Weight: Novel Central Metabolic Action of Oligosomatostatin Receptor Agonist in Rats (2009) (0)
Antagonists modified at positions 5 and 6 gnrh. (1998) (0)
CHARACTERIZATION OF CORTICOTROPIN AND GROWTH HORMONE RELEASING FACTOR. (1983) (0)
Synthetic peptide and the pharmaceutical agent containing the peptide or a nontoxic salt thereof (1985) (0)
A process for preparing a peptide which inhibits the release of gonadotropins by the pituitary gland of mammals (1983) (0)
Total synthesis of TASP 4a molecules by solid phase methods (1990) (0)
SAR of corticotropin releasing factor in relation to its pituitary receptor and binding protein (1995) (0)
Synthesis of a cyclic analog of the luteinizing hormone releasing factor: [Glu4,D-Ala6,Orn7]LRF. (1977) (0)
Gonadotropin releasing hormone antagonists with acyl substitutions of 4-aminophenylalanine at positions 5 and 6 (1995) (0)
Synthetic GRF analog peptides and pharmaceutically acceptable salts thereof, and pharmaceutical composition containing the peptide or a nontoxic salt thereof (1985) (0)
141 Peripheral Corticotropin-Releasing Factor (CRF) Enhances Colonic Mucin Secretion and Modulates MUC2 and MUC4 Gene Expression in Rats: Differential Role of CRF Receptors (2010) (0)
Corticotropin Releasing Factor/Urocortin Network of Ligands and Their Receptors (2008) (0)
Brain stimulation of somatostatin 2 receptors stimulates feeding in mice: Analysis of food intake pattern (2010) (0)
In vivo activities of conantokin-G analogs (1994) (0)
Antagonists selective for somatostatin receptor (SSTR2) (2007) (0)
Growth Hormone Releasing Hormone: Therapeutic Potentials (1987) (0)
Synthesis and characterization of DOTA-coupled dimeric Y1 receptors antagonists for breast cancer targeting (2011) (0)
Contents, Vol. 2, 1971/72 (1971) (0)
Calcitonin gene related peptide: immunohistochemical localization, specific binding and biological actions in the pancreas (1985) (0)
Synthetic grf peptide (1985) (0)
Structurally constrained LHRH analogs (1984) (0)
Unexpected sensitivity of SST2 antagonists to radiometal modifications (2012) (0)
Solid-state NMR sequential assignment of the β-endorphin peptide in its amyloid form (2016) (0)
Process for the preparation of pharmaceutically useful analogs of GRF (1985) (0)
Peptides d'urocortine (1996) (0)
Urocortinproteiner and uses thereof (2001) (0)
CRFR1 selective ligand (2002) (0)
Central Action of Pan-Somatostatin Agonist ODT-8 to Prevent Abdominal Surgery-Induced Reduction of Circulating Acyl Ghrelin, Gastric Emptying and Food Intake (2011) (0)
Corticotropin Releasing Factor (CRF) and Urocortins (Ucns) Chimeras (2013) (0)
Novel nicotinic receptor ligands (1994) (0)
Peptides, process for their preparation and pharmaceutical compositions containing them (1976) (0)
Therapeutic Effects of Growth Hormone Releasing Hormone (1988) (0)
Subject Index, Vol. 28, 1987 (1987) (0)
Original pieces for saxophone quartet (1987) (0)
SOMATOSTATIN, TOTAL SOLID PHASE SYNTHESIS (1974) (0)
Erratum (1983) (0)
Solid‐Phase Synthesis of Peptide Amides on a Polystyrene Support Using Fluorenylmethoxycarbonyl Protecting Groups. (1987) (0)
Systematic lactam scan of hGRF 1-29-NH2 yields potent agonists and antagonists (2002) (0)
GROWTH HORMONE (GH) RELEASE IN CHILDREN WITH SHORT STATURE: STIMULATION BY HUMAN PANCREATIC TUMOR GROWH HORMONE RELEASING FACTOR-40 (hpGRF-40) (1984) (0)
309 – CHARACTERIZATION OF THE BOMBESIN RECEPTOR IN MAMMALIAN BRAIN (1978) (0)
Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF2 (2002) (0)
ANGIOTENSIN PART 2, SYNTHESIS AND BIOLOGICAL ACTIVITY OF 6-(1-METHYLHISTIDINE) AND 6-(3-METHYLHISTIDINE) ANALOGS (1973) (0)
W1930 The Oligosomatostatin Receptor Agonist Odt8-Sst Inhibits Basal and Stress-Stimulated Propulsive Colonic Motor Function in Mice (2010) (0)
Effect of Analogues of Somatostatin on Pancreatic and Gut Hormones and Growth Hormone in Man (1979) (0)
Running title : Analog regulation of sst 2 signaling and endocytosis (2005) (0)
antagonists in position 5 and 6 modified gonadotropin-releasing hormone (GnRH) (1998) (0)
acyltransferase levels in rats: role of the somatostatin receptor (2011) (0)
3D NMR structure of astressin (2007) (0)
Subject Index Vol. 59, 1994 (1994) (0)
Process for the preparation of therapeutically useful CRF analogs (1992) (0)
Process for the preparation of therapeutically useful peptides (1990) (0)
The Symposium Test Peptide (STP): Synthesis and Characterization of a Model Peptide (1987) (0)
53 – DESIGN AND SYNTHESIS OF SYMPOSIUM TEST PEPTIDE-3 (STP-3) (1989) (0)
Differential role of CRF receptor 1 (CRF-R1) and CRF-R2 in peripheral CRF or stress-induced inhibition of gastric emptying and stimulation of colonic transit in rats (2001) (0)
Melanin concentrating hormone and DNA for the expression of the same (1990) (0)
Cysteine in Peptide Chemistry: Side Reactions Associated with and Strategies for the Handling of Peptides Containing Cysteine, (1992) (0)
Ligands selectifs crfr1 (2002) (0)
French music for violin and cello (1985) (0)
gastric and colonic smooth muscle cells Expression of somatostatin receptor subtypes on guinea pig (2011) (0)
Abstracts of Selected Free Communications (1986) (0)
GAMMA+lRLANOTROPIN RESPONSE TO OVINE CORTICOTROPIN RELEASING FACTOR IN NORHAL RDtUNS (1987) (0)
Systemin the Amphibian Sympathetic Nervous -Conotoxins PVIA and SVIE on Sodium δ Effects of (2015) (0)
In Vitro and In Vivo Characterization of Conantokin-R , a Selective NMDA Receptor Antagonist Isolated from the Venom of the Fish-Hunting Snail Conus radiatus 1 (1999) (0)
S1824 Selective Peripheral Activation of Corticotropin-Releasing Factor (CRF) Receptor Type 1 (CRF1) By Cortagine: A New Model of IBS-D-Like Symptoms in Rodents (2008) (0)
Conformational Analysis of a Highly Potent, Constrained Gonadotropin‐ Releasing Hormone Antagonist. Part 1. NMR. (1992) (0)
Structure activity relationships (SAR) of corticotropin releasing factor (1995) (0)
Flute music of the 20th century (2002) (0)
Competitive antagonists of peptide hormones (1987) (0)
High affinity, truncated, cyclic and branched analogs of Neuropeptide Y (1994) (0)
Human Urocortin 3 (2008) (0)
Conotope phage libraries (1992) (0)
HpGRF-analogous peptides, non-toxic salts thereof and composition containing these (1984) (0)
Intestinal CRF Receptor Subtypes Mediate Distinct Intestinal Barrier Function Responses Through Intestinal Mast Cell Activation (2011) (0)
The Journal of Comparative Neurology, Table of Content, Vol. 525, No. 18, December 15, 2017 (2017) (0)
Analogifremgangsmaade for the preparation of LRF analogs nona- or decapeptidamider or non-toxic salts thereof and nona- or decapeptide derivatives for use as starting materials in the process (1980) (0)
[PRO7,13] AA-CONOTOXIN PIVA, NMR, 12 STRUCTURES (1997) (0)
27 Growth Hormone-Releasing Factor (1986) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jean Edouard Frederic P. Rivier?

Jean Edouard Frederic P. Rivier is affiliated with the following schools: